"rationale","uuid:ID","id","label","description","name"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","ef73fa0a-6bd0-48e8-abe5-f374632425ff","StudyDesign_1","","The main design for the study","Study Design 1"
